ScholarWorks@SUNGKYUNKWAN UNIVERSITY

Investigational New Drugs

Journal Title

  • Investigational New Drugs

ISSN

  • E 1573-0646 | P 0167-6997 | 1573-0646 | 0167-6997

Publisher

  • Kluwer Academic Publishers
  • Springer Nature

Listed on(Coverage)

JCR1997-2019
SJR1999-2019
CiteScore2011-2019
SCI2010-2019
SCIE2010-2021
CC2016-2021
SCOPUS2017-2020
MEDLINE2016-2021
EMBASE2016-2020

Active

  • Active

    based on the information

    • SCOPUS:2020-10

Country

  • NETHERLANDS

Aime & Scopes

  • The development of new anticancer agents is one of the most rapidly changing aspects of cancer research. Investigational New Drugs provides a forum for the rapid dissemination of information on new anticancer agents. The papers published are of interest to the medical chemist, toxicologist, pharmacist, pharmacologist, biostatistician and clinical oncologist. Investigational New Drugs provides the fastest possible publication of new discoveries and results for the whole community of scientists developing anticancer agents. Each issue contains original articles dealing with anticancer drug development. Other sections are devoted to invited review articles and letters to the editor. The journal also affords the opportunity to publish the proceedings of special workshops and symposia devoted to the development of new anticancer agents. Provided they add to the understanding of the investigational agents, the journal is not adverse to publishing clinical trials with negative results. Investigational New Drugs cuts across all the usual lines or subdisciplines, providing a locus for the presentation of relevant investigations and the discussion of critical questions appropriate to the entire field of new anticancer drug development.

Homepage

Article List

1 - 20 out of 46 results.

SCIESCOPUS
ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non-small cell lung cancer

Ku, BM[Ku, Bo Mi]; Heo, JY[Heo, Jae Yeong]; Kim, J[Kim, Jinchul]; Sun, JM[Sun, Jong-Mu]; Lee, SH[Lee, Se-Hoon]; Ahn, JS[Ahn, Jin Seok]; Park, K[Park, Keunchil]; Ahn, MJ[Ahn, Myung-Ju]

ArticleIssue Date2022CitationINVESTIGATIONAL NEW DRUGS, v.40, no.2, pp.265 - 273PublisherSPRINGER
SCIESCOPUS
A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors

Keam, B[Keam, Bhumsuk]; Ock, CY[Ock, Chan-Young]; Kim, TM[Kim, Tae Min]; Oh, D[Oh, Do-Youn]; Kang, WK[Kang, Won Ki]; Park, YH[Park, Yeon Hee]; Lee, J[Lee, Jeeyun]; Lee, JH[Lee, Ji Hye]; Ahn, YH[Ahn, Yoen Hee]; Kim, HJ[Kim, Hyeon Ju], et al.

ArticleIssue Date2021CitationINVESTIGATIONAL NEW DRUGS, v.39, no.6, pp.1624 - 1632PublisherSPRINGER
SCIESCOPUS
A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer

Jeong, H[Jeong, Hyehyun]; Hong, YS[Hong, Yong Sang]; Kim, JE[Kim, Jeong Eun]; Lim, HS[Lim, Hyeong-Seok]; Ahn, JB[Ahn, Joong Bae]; Shin, SJ[Shin, Sang Joon]; Park, YS[Park, Young Suk]; Kim, ST[Kim, Seung Tae]; Han, SW[Han, Sae-Won]; Kim, TY[Kim, Tae-You], et al.

ArticleIssue Date2021CitationINVESTIGATIONAL NEW DRUGS, v.39, no.5, pp.1335 - 1347PublisherSPRINGER
SCIESCOPUS
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (vol 45, pg 810, 2020)

Kroschinsky, F[Kroschinsky, Frank]; Middeke, JM[Middeke, Jan Moritz]; Janz, M[Janz, Martin]; Lenz, G[Lenz, Georg]; Witzens-Harig, M[Witzens-Harig, Mathias]; Bouabdallah, R[Bouabdallah, Reda]; La Rosee, P[La Rosee, Paul]; Viardot, A[Viardot, Andreas]; Salles, G[Salles, Gilles]; Kim, SJ[Kim, Seok Jin], et al.

ArticleIssue Date2021CitationINVESTIGATIONAL NEW DRUGS, v.39, no.1, pp.283 - 284PublisherSPRINGER
SCIESCOPUS
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma (vol 32, pg 861, 2020)

Kroschinsky, F[Kroschinsky, Frank]; Middeke, JM[Middeke, Jan Moritz]; Janz, M[Janz, Martin]; Lenz, G[Lenz, Georg]; Witzens-Harig, M[Witzens-Harig, Mathias]; Bouabdallah, R[Bouabdallah, Reda]; La Rosee, P[La Rosee, Paul]; Viardot, A[Viardot, Andreas]; Salles, G[Salles, Gilles]; Kim, SJ[Kim, Seok Jin], et al.

ArticleIssue Date2021CitationINVESTIGATIONAL NEW DRUGS, v.39, no.1, pp.285 - 286PublisherSPRINGER
SCIESCOPUS
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Kroschinsky, F[Kroschinsky, Frank]; Middeke, JM[Middeke, Jan Moritz]; Janz, M[Janz, Martin]; Lenz, G[Lenz, Georg]; Witzens-Harig, M[Witzens-Harig, Mathias]; Bouabdallah, R[Bouabdallah, Reda]; La Rosee, P[La Rosee, Paul]; Viardot, A[Viardot, Andreas]; Salles, G[Salles, Gilles]; Kim, SJ[Kim, Seok Jin], et al.

ArticleIssue Date2020CitationINVESTIGATIONAL NEW DRUGS, v.38, no.5, pp.1472 - 1482PublisherSPRINGER
SCIESCOPUS
Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer

Ku, BM[Ku, Bo Mi]; Bae, YH[Bae, Yeon Hee]; Lee, KY[Lee, Kyoung Young]; Sun, JM[Sun, Jong-Mu]; Lee, SH[Lee, Se-Hoon]; Ahn, JS[Ahn, Jin Seok]; Park, K[Park, Keunchil]; Ahn, MJ[Ahn, Myung-Ju]

ArticleIssue Date2020CitationINVESTIGATIONAL NEW DRUGS, v.38, no.2, pp.360 - 368PublisherSPRINGER
SCIESCOPUS
A phthalimidoalkanamide derived novel DNMT inhibitor enhanced radiosensitivity of A549 cells by inhibition of homologous recombination of DNA damage

Kang, HC[Kang, Hyun-Cheol]; Chie, EK[Chie, Eui Kyu]; Kim, HJ[Kim, Hak Jae]; Kim, JH[Kim, Jin Ho]; Kim, IH[Kim, Il Han]; Kim, K[Kim, Kwangsoo]; Shin, BS[Shin, Beom Su]; Ma, E[Ma, EunSook]

ArticleIssue Date2019CitationINVESTIGATIONAL NEW DRUGS, v.37, no.6, pp.1158 - 1165PublisherSPRINGER
SCIESCOPUS
Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma

Yoo, C[Yoo, Changhoon]; Park, JW[Park, Joong-Won]; Kim, YJ[Kim, Yoon Jun]; Kim, DY[Kim, Do Young]; Yu, SJ[Yu, Su Jong]; Lim, TS[Lim, Tae Seop]; Lee, SJ[Lee, Su Jin]; Ryoo, BY[Ryoo, Baek-Yeol]; Lim, HY[Lim, Ho Yeong]

ArticleIssue Date2019CitationINVESTIGATIONAL NEW DRUGS, v.37, no.3, pp.567 - 572PublisherSPRINGER
SCIESCOPUS
Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores

Hwang, I[Hwang, Inhwan]; Kang, J[Kang, Jihoon]; Ip, HNN[Ip, Hei Nga Natalie]; Jeong, JH[Jeong, Jae Ho]; Kim, KP[Kim, Kyu-pyo]; Chang, HM[Chang, Heung-Moon]; Yoo, C[Yoo, Changhoon]; Ryoo, BY[Ryoo, Baek-Yeol]

ArticleIssue Date2019CitationINVESTIGATIONAL NEW DRUGS, v.37, no.3, pp.584 - 590PublisherSPRINGER
SCIESCOPUS
Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients

Tak, WY[Tak, Won Young]; Ryoo, BY[Ryoo, Baek-Yeol]; Lim, HY[Lim, Ho Yeong]; Kim, DY[Kim, Do-Young]; Okusaka, T[Okusaka, Takuji]; Ikeda, M[Ikeda, Masafumi]; Hidaka, H[Hidaka, Hisashi]; Yeon, JE[Yeon, Jong-Eun]; Mizukoshi, E[Mizukoshi, Eishiro]; Morimoto, M[Morimoto, Manabu], et al.

ArticleIssue Date2018CitationINVESTIGATIONAL NEW DRUGS, v.36, no.6, pp.1072 - 1084PublisherSPRINGER
SCIESCOPUS
Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy

Cho, H[Cho, Hyungwoo]; Yoon, DH[Yoon, Dok Hyun]; Kim, KP[Kim, Kyu-pyo]; Bae, KS[Bae, Kyun-Seop]; Kim, WS[Kim, Won Seog]; Eom, HS[Eom, Hyeon-Seok]; Kim, JS[Kim, Jin Seok]; Hong, JY[Hong, Jung Yong]; Kim, SJ[Kim, Seok Jin]; Lee, H[Lee, Hyewon], et al.

ArticleIssue Date2018CitationINVESTIGATIONAL NEW DRUGS, v.36, no.5, pp.877 - 885PublisherSPRINGER
SCIESCOPUS
Drug repurposing screening identifies bortezomib and panobinostat as drugs targeting cancer associated fibroblasts (CAFs) by synergistic induction of apoptosis

Lee H.-M.[Lee H.-M.]; Lee E.[Lee E.]; Yeo S.-Y.[Yeo S.-Y.]; Shin S.[Shin S.]; Park H.-K.[Park H.-K.]; Nam D.-H.[Nam D.-H.]; Kim S.-H.[Kim S.-H.]

ArticleIssue Date2018CitationInvestigational New Drugs, v.36, no.4, pp.545 - 560PublisherSpringer New York LLC
SCIESCOPUS
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis

Kang, J[Kang, Jihoon]; Hwang, I[Hwang, Inhwan]; Yoo, C[Yoo, Changhoon]; Kim, KP[Kim, Kyu-pyo]; Jeong, JH[Jeong, Jae Ho]; Chang, HM[Chang, Heung-Moon]; Lee, SS[Lee, Sang Soo]; Park, DH[Park, Do Hyun]; Song, TJ[Song, Tae Jun]; Seo, DW[Seo, Dong Wan], et al.

ArticleIssue Date2018CitationINVESTIGATIONAL NEW DRUGS, v.36, no.4, pp.732 - 741PublisherSPRINGER
SCIESCOPUS
Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors

Lee, SJ[Lee, Su Jin]; Lee, SY[Lee, Seon Young]; Lee, WS[Lee, Weon Sup]; Yoo, JS[Yoo, Jin San]; Sun, JM[Sun, Jong-Mu]; Lee, J[Lee, Jeeyun]; Park, SH[Park, Se Hoon]; Park, JO[Park, Joon Oh]; Ahn, MJ[Ahn, Myung-Ju]; Lim, HY[Lim, Ho Yeong], et al.

ArticleIssue Date2017CitationINVESTIGATIONAL NEW DRUGS, v.35, no.6, pp.782 - 790PublisherSPRINGER
SCIESCOPUS
Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry

Cho, J[Cho, Jinhyun]; Ahn, S[Ahn, Soomin]; Yoo, KH[Yoo, Kwai Han]; Kim, JH[Kim, Jung Han]; Choi, SH[Choi, Sang-Hee]; Jang, KT[Jang, Kee-Taek]; Lee, J[Lee, Jeeyun]

ArticleIssue Date2016CitationINVESTIGATIONAL NEW DRUGS, v.34, no.6, pp.677 - 684PublisherSPRINGER
SCIESCOPUS
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer

Scagliotti, G[Scagliotti, Giorgio]; Kang, JH[Kang, Jin Hyoung]; Smith, D[Smith, David]; Rosenberg, R[Rosenberg, Richard]; Park, K[Park, Keunchil]; Kim, SW[Kim, Sang-We]; Su, WC[Su, Wu-Chou]; Boyd, TE[Boyd, Thomas E.]; Richards, DA[Richards, Donald A.]; Novello, S[Novello, Silvia], et al.

ArticleIssue Date2016CitationINVESTIGATIONAL NEW DRUGS, v.34, no.5, pp.625 - 635PublisherSPRINGER
SCIESCOPUS
AZD9291 overcomes T790 M-mediated resistance through degradation of EGFRL858R/T790M in non-small cell lung cancer cells

Ku B.M.[Ku B.M.]; Bae Y.-H.[Bae Y.-H.]; Koh J.[Koh J.]; Sun J.-M.[Sun J.-M.]; Lee S.-H.[Lee S.-H.]; Ahn J.S.[Ahn J.S.]; Park K.[Park K.]; Ahn M.-J.[Ahn M.-J.]

ArticleIssue Date2016CitationInvestigational New Drugs, v.34, no.4, pp.407 - 415PublisherSpringer New York LLC
SCIESCOPUS
Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose

Venkatakrishnan, K[Venkatakrishnan, Karthik]; Kim, TM[Kim, Tae Min]; Lin, CC[Lin, Chia-Chi]; Thye, LS[Thye, Lim Soon]; Chng, WJ[Chng, Wee Joo]; Ma, B[Ma, Brigette]; Chen, MH[Chen, Ming Huang]; Zhou, XF[Zhou, Xiaofei]; Liu, H[Liu, Hua]; Kelly, V[Kelly, Virginia], et al.

ArticleIssue Date2015CitationINVESTIGATIONAL NEW DRUGS, v.33, no.4, pp.942 - 953PublisherSPRINGER
SCIESCOPUS
BYL719, a selective inhibitor of phosphoinositide 3-Kinase alpha, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer

Ku, BM[Ku, Bo Mi]; Jho, EH[Jho, Eun Hye]; Bae, YH[Bae, Yeon-Hee]; Sun, JM[Sun, Jong-Mu]; Ahn, JS[Ahn, Jin Seok]; Park, K[Park, Keunchil]; Ahn, MJ[Ahn, Myung-Ju]

ArticleIssue Date2015CitationINVESTIGATIONAL NEW DRUGS, v.33, no.1, pp.12 - 21PublisherSPRINGER
1 2 3
STATISTICS
Total View :5,312,164
Today View :0

RSS_1.0 RSS_2.0 ATOM_1.0

CONTACT US

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu

COPYRIGHT © 2021 SUNGKYUNKWAN UNIVERSITY ALL RIGHTS RESERVED.

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

BROWSE

한국어